The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high surgical risk. We included 120 patients with a mean age of 84 years and the aortic valve area of 0.7 cm2. The device was successfully implanted in all patients with a 15% rate of moderate to severe aortic regurgitation after implantation and 28% of pacemaker requirement. No migration or embolization of the valve was observed. A 30-days, mortality was 4.2% and stroke 1.7%.
9_ian_meredith
Ian Meredith
2013-10-31
Original title: REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis
